

Whitney P Kirschbrown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7458769/publications.pdf>

Version: 2024-02-01

14
papers

352
citations

1163117
8
h-index

996975
15
g-index

15
all docs

15
docs citations

15
times ranked

627
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. <i>Nanomedicine</i> , 2015, 10, 447-463.	3.3	67
2	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 85-97.	10.7	64
3	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2667-2675.	1.6	58
4	Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1025-1032.	2.3	54
5	Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 702-716.	2.0	24
6	Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. <i>Hematological Oncology</i> , 2019, 37, 464-473.	1.7	21
7	Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 329-340.	2.3	21
8	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. <i>International Journal of Nanomedicine</i> , 2015, 10, 1201.	6.7	16
9	Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1147-1158.	2.3	8
10	Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 539-550.	2.3	7
11	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 866-872.	1.4	4
12	Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 499-512.	2.3	4
13	Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1096-1105.	2.0	2
14	Reply to J. Wei et al. <i>Journal of Clinical Oncology</i> , 2021, , JCO2101973.	1.6	1